Last $24.51 USD
Change Today -0.05 / -0.20%
Volume 620.2K
QGEN On Other Exchanges
Symbol
Exchange
Xetra
NASDAQ GS
As of 8:10 PM 07/10/14 All times are local (Market data is delayed by at least 15 minutes).

qiagen n.v. (QGEN) Snapshot

Open
$24.15
Previous Close
$24.56
Day High
$24.51
Day Low
$24.10
52 Week High
06/20/14 - $24.83
52 Week Low
04/15/14 - $19.46
Market Cap
5.7B
Average Volume 10 Days
770.6K
EPS TTM
$0.66
Shares Outstanding
232.3M
EX-Date
--
P/E TM
37.0x
Dividend
--
Dividend Yield
--
Current Stock Chart for QIAGEN N.V. (QGEN)

qiagen n.v. (QGEN) Related Businessweek News

No Related Businessweek News Found

qiagen n.v. (QGEN) Details

QIAGEN N.V., through its subsidiaries, provides sample and assay technologies worldwide. It offers approximately 500 core consumable products, such as sample and assay kits, and automated instrumentation systems that empower customers to transform raw biological samples into molecular information. The company’s consumable products are used for plasmid deoxyribonucleic acid (DNA) purification, and ribonucleic acid purification and stabilization; genomic and viral nucleic acid purification; nucleic acid transfection; polymerase chain reaction (PCR) amplification; reverse transcription; DNA cleanup after PCR and sequencing; and DNA cloning and protein purification. The company sells the digene HC2 HPV Test, a test for high-risk strains of the human papillomavirus. It also offers co-development services for companion diagnostics, technology licensing and patent sales services, and custom services, including whole genome amplification, DNA sequencing, and non-cGMP DNA production on a contract basis. In addition, the company provides instrumentation systems that automate the use of sample and assay technologies into solutions for a range of laboratory needs enabling customers to perform nucleic acid sample preparation, assay setup, and target detection, as well as workflow solutions. Its automated systems include QIAsymphony, a modular system; Rotor-Gene Q, a rotary real-time PCR cycler system; PyroMark, a high-resolution detection platform based upon the Pyrosequencing technology; QIAcube, a sample processing instrument; QIAxcel for nucleic acid separation in low- to high-throughput laboratories; and ESE-Quant Tube Scanners, an optical measurement device. The company serves molecular diagnostics laboratories; applied testing customers in fields, such as forensics, veterinary diagnostics, and food safety; pharmaceutical research and development groups, and academic researchers. QIAGEN N.V. was founded in 1986 and is headquartered in Venlo, the Netherlands.

4,000 Employees
Last Reported Date: 05/8/14
Founded in 1986

qiagen n.v. (QGEN) Top Compensated Officers

Chairman of Management Board, Chief Executive...
Total Annual Compensation: $1.5M
Chief Financial Officer, Managing Director an...
Total Annual Compensation: $639.5K
Compensation as of Fiscal Year 2013.

qiagen n.v. (QGEN) Key Developments

Qiagen NV - Shareholder/Analyst Call

Annual General Meeting

QIAGEN Receives FDA Approval of artus(R) CMV RGQ MDx Kit to Monitor Cytomegalovirus (CMV) Viral Load in Organ Transplant Patients

Qiagen NV announced that its artus(R) CMV RGQ MDx Kit for human cytomegalovirus (CMV) has been approved by the U.S. Food and Drug Administration (FDA) under a full premarket approval (PMA). The test is the only FDA-approved PCR-based assay optimized for low- to mid-throughput testing of CMV. With a turn-around time of approximately three hours, the assay provides faster results than other PMA approved tests. artus CMV RGQ MDx runs on QIAGEN's Rotor-Gene Q MDx real-time PCR platform, which was cleared by the FDA in 2012 and is a member of the QIAsymphony modular family of automated instruments. The CE-marking of artus(R) GBS QS-RGQ Kit for detection of Group B Streptococcus (GBS) represents the most recent addition to QIAGEN's growing QIAsymphony test menu. The test was developed in partnership with Intelligent MDx. For healthcare-associated infections, QIAGEN already offers the CE-marked artus VanR QS-RGQ Kit for vancomycin-resistant bacteria, the artus C. difficile QS-RGQ Kit and the artus MRSA/SA QS-RGQ Kit for detection of methicillin-resistant Staphylococcus aureus infections (MRSA).

Qiagen NV Presents at Goldman Sachs 35th Annual Global Healthcare Conference, Jun-11-2014 02:40 PM

Qiagen NV Presents at Goldman Sachs 35th Annual Global Healthcare Conference, Jun-11-2014 02:40 PM. Venue: Terranea Resort in Rancho Palos Verdes, 100 Terranea Way, Los Angeles, California, United States.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
QGEN:US $24.51 USD -0.05

QGEN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
BioMerieux €78.45 EUR -1.11
Cepheid $47.80 USD +0.048
Hologic Inc $25.48 USD -0.03
Myriad Genetics Inc $37.60 USD -0.10
PerkinElmer Inc $46.69 USD -0.17
View Industry Companies
 

Industry Analysis

QGEN

Industry Average

Valuation QGEN Industry Range
Price/Earnings 100.0x
Price/Sales 4.3x
Price/Book 2.1x
Price/Cash Flow 116.4x
TEV/Sales 3.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact QIAGEN N.V., please visit www.qiagen.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.